What is Primidone?
Primidone is an antiepileptic drug used to control grand mal (generalized tonic-clonic), psychomotor (complex partial), and focal epileptic seizures, and is also a first-line treatment for essential tremor. 1
Mechanism and Pharmacology
Primidone is not a prodrug but is active by itself, though it is metabolized to two active compounds: phenyl-ethyl-malonamide (PEMA) and phenobarbital 2. Interestingly, primidone itself appears to have independent anticonvulsant activity, as evidenced by studies showing therapeutic effects even when derived phenobarbital levels remain subtherapeutic 3.
The therapeutic serum level for primidone is 5-12 mcg/mL (23-46 mmol/L) 1, 2. However, the rate of conversion to phenobarbital is highly variable between individuals 2.
Clinical Indications
Epilepsy
- Grand mal (generalized tonic-clonic) seizures
- Psychomotor (complex partial) seizures
- Focal epileptic seizures
- May control grand mal seizures refractory to other anticonvulsants 1
Essential Tremor
Primidone remains a first-line treatment for essential tremor despite being less commonly prescribed for epilepsy 2. Studies demonstrate that primidone is more effective than propranolol in reducing tremor amplitude 4.
Dosing Guidelines
Adults and Children Over 8 Years
Initial titration schedule 1:
- Days 1-3: 100-125 mg at bedtime
- Days 4-6: 100-125 mg twice daily
- Days 7-9: 100-125 mg three times daily
- Day 10 onward (maintenance): 250 mg three times daily
Maintenance dosing: 750-1000 mg/day in divided doses (250 mg 3-4 times daily). Maximum dose should not exceed 500 mg four times daily (2000 mg/day) 1.
Children Under 8 Years
Initial titration 1:
- Days 1-3: 50 mg at bedtime
- Days 4-6: 50 mg twice daily
- Days 7-9: 100 mg twice daily
- Day 10 onward: 125-250 mg three times daily
Maintenance: 10-25 mg/kg/day in divided doses 1.
Essential Tremor Dosing
Low doses (250 mg/day) are equally or more effective than high doses (750 mg/day) for essential tremor control, with significantly fewer side effects and better tolerability 5. The response is maintained for at least 12 months 5.
Critical Safety Considerations
Acute Intolerance (Major Pitfall)
Up to 82% of patients experience acute neurotoxic symptoms after the first dose of primidone, including somnolence, ataxia, confusion, dizziness, and nausea 6. This is the most common reason for treatment discontinuation.
Prevention strategy: Pre-treatment with phenobarbital 10 mg/day for 2-3 weeks before initiating primidone reduces acute intolerance from 82% to 17% through functional cross-tolerance 7, 6. This approach allows starting primidone at 500 mg/day rather than the gradual titration, with minimal adverse effects in 87% of patients 7.
Contraindications
- Porphyria (absolute contraindication)
- Phenobarbital allergy 1
Important Warnings
- Suicidal ideation: Like all antiepileptic drugs, primidone carries a risk of suicidal thoughts or actions (approximately 1 in 500 patients) 1
- Abrupt discontinuation: Never stop primidone suddenly—can precipitate status epilepticus in epilepsy patients 1
- Pregnancy: May harm the fetus; patients should be enrolled in the NAAED Pregnancy Registry (1-888-233-2334) 1
Common Side Effects
- Behavioral disturbances, irritability, sleep disturbances 3
- Drowsiness and sedation (concentration-dependent)
- Acute reactions to initial dosing (see above)
Therapeutic Drug Monitoring
TDM of primidone is considered "probably useless" as a standalone measure 2. When monitoring is performed, both primidone AND phenobarbital levels must be measured together, as phenobarbital contributes significantly to therapeutic effect 2. The therapeutic range for phenobarbital is 10-40 mg/L (43-172 mmol/L) 2.
Notably, therapeutic response does not correlate with serum levels in essential tremor 4, and a single 250 mg dose can decrease tremor by 60% with stable primidone levels but undetectable phenobarbital levels 4.
Transitioning from Other Anticonvulsants
When switching from other anticonvulsants, start primidone at 100-125 mg at bedtime and gradually increase while simultaneously tapering the other drug. This transition should take at least 2 weeks 1.